Long-Term Outcomes of Metabolic and Bariatric Surgery: Durability of Weight Loss, Metabolic Remission, and the Changing Treatment Landscape Authors: Yoonhong Kim, Ki Hyun Kim, Seung Hun Lee, Yeajin Moon, Yeongdo Oh, Kyung Won Seo Published: 2026 ABSTRACT Obesity is a chronic, relapsing disease that leads to significant metabolic, cardiovascular, and functional consequences. Metabolic and bariatric surgery (MBS) remains the most effective evidence-based treatment for achieving substantial and lasting weight loss. Additionally, the emergence of incretin-based pharmacotherapy has transformed the long-term treatment landscape. Long-term studies demonstrate that MBS results in sustained weight reduction, durable improvements in type 2 diabetes, hypertension, and dyslipidemia, as well as lower risks of cardiovascular morbidity and all-cause mortality when compared to conventional care. However, long-term outcomes and risk profiles vary among different surgical procedures. Roux-en-Y gastric bypass typically yields better long-term metabolic and weight outcomes than older restrictive procedures and, in certain cases, sleeve gastrectomy. While sleeve gastrectomy is effective, it raises concerns about reflux-related complications over time. More malabsorptive procedures, such as the duodenal switch, may achieve greater weight loss in patients with severe obesity but come with a higher nutritional burden and late adverse events. Overall, current evidence supports MBS as a treatment that modifies the disease rather than simply a weight-loss procedure. Its long-term value should be evaluated not only by changes in weight but also by the durability of metabolic improvements, procedure-specific trade-offs, and the quality of lifelong multidisciplinary follow-up. In current practice, incretin-based pharmacotherapy should be considered as an alternative, adjunct, or sequential strategy in conjunction with MBS. INTRODUCTION Obesity is a complex chronic disease that significantly contributes to conditions such as type 2 diabetes (T2D), hypertension, cardiovascular disease, and premature death. In recent decades, metabolic and bariatric surgery (MBS) has evolved from a procedure focused solely on weight loss to one recognized as a metabolic intervention with extensive physiological effects. This transformation is highlighted in the 2022 American Society for Metabolic and Bariatric Surgery (ASMBS)/International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO) joint statement, which recommends MBS for patients with a body mass index (BMI) >35 kg/m2 regardless of comorbidity status, and suggests considering surgery for individuals with metabolic diseases at lower BMI thresholds [1]. However, the true value of MBS cannot be assessed through short-term postoperative outcomes alone. While early excess weight loss (EWL) is significant, it does not address the critical question of whether surgery can alter the long-term trajectory of obesity and its related complications. Thus, long-term follow-up studies and extended randomized controlled trials are vital for determining the role of MBS in contemporary obesity treatment [234]. Much of the current evidence stems from several landmark studies. The Swedish Obese Subjects (SOS) study indicated that MBS is linked to reduced all-cause mortality and lower cardiovascular morbidity [25]. The Utah gastric bypass cohort later demonstrated sustained weight loss and long-term remission or prevention of metabolic comorbidities over a 12-year period [3]. More recently, the ARMMS-T2D collaborative analysis provided randomized evidence extending to 12 years, revealing that surgery continued to offer better glycemic control and reduced medication use compared to intensive medical and lifestyle treatments [4]. Long-term outcomes also differ by procedure type. Historically, Roux-en-Y gastric bypass (RYGB) has demonstrated greater durability compared to laparoscopic adjustable gastric banding [6]. Comparative studies of sleeve gastrectomy (SG) and RYGB indicate that both procedures are effective; however, SG may be associated with a higher long-term risk of reflux [7]. For patients with severe obesity, procedures like duodenal switch (DS) may lead to greater weight loss but come with increased nutritional and procedural risks [8]. The treatment landscape has evolved further with the introduction of highly effective incretin-based pharmacotherapy. Semaglutide and tirzepatide have achieved substantial weight loss in adults with overweight or obesity, and tirzepatide showed greater weight reduction than semaglutide in adults with obesity but without diabetes [910]. In adults with obesity and prediabetes, three-year tirzepatide data further suggested sustained weight loss and a lower risk of progression to T2D [11]. Nonetheless, since these benefits seem closely linked to ongoing treatment, the long-term efficacy of pharmacotherapy compared to the anatomical and physiological benefits of MBS remains uncertain [1213]. MBS should be regarded as the starting point for long-term disease management rather than a one-time procedure. The same body of evidence supporting its effectiveness also highlights potential late complications, such as anemia, bone disease, and the necessity for revisional procedures [41415]. This balance between benefits and risks is especially crucial for adolescents, whose metabolic response may be robust, yet long-term monitoring is essential [1617]. Furthermore, the interpretation of long-term outcomes has been complicated by inconsistent terminology; however, recent statements from the IFSO have begun to standardize these concepts and their postoperative management [1819]. In this review, long-term outcomes are discussed primarily in studies extending beyond the early postoperative period, with particular emphasis on follow-up of 5 years or longer. Because definitions vary across literature, study-specific definitions were retained whenever available. In broader terms, weight regain refers to post-nadir weight increase after initial postoperative weight loss; remission, to achievement of disease-specific targets without ongoing disease-specific pharmacotherapy when so defined in the original study; clinical control, to meaningful improvement in disease severity or medication burden short of full remission; and durability, to the persistence of these benefits over time. Within this framework, recurrence or relapse is more appropriately understood as part of the chronic-course management of obesity and its related complications rather than as a simple binary treatment failure. This review summarizes the long-term evidence for MBS across five key areas: survival and cardiovascular outcomes, durability of metabolic remission, procedure-specific trade-offs, late complications, and the role of MBS in the era of incretin-based pharmacotherapy. Landmark studies that form the foundation of this evidence are summarized in Table 1. Table 1Landmark studies informing long-term outcomes after MBSStudyDesign/populationFollow-upComparison/procedureKey long-term findingsInterpretive contributionSwedish Obese Subjects [25]Prospective controlled cohort; adults with obesity>20 yearsMBS vs. usual careLower long-term mortality, fewer cardiovascular events, longer life expectancy after surgeryEstablishes major long-term outcomes: survival and cardiovascular benefitUtah gastric bypass cohort [3]Prospective observational cohort; adults with obesity12 yearsRYGB vs. nonsurgical controlsDurable weight loss; remission or prevention of T2DM, HTN, and dyslipidemiaEstablishes metabolic durabilityARMMS-T2D [4]Pooled long-term follow-up of 4 randomized clinical trials; adults with obesity and T2DM7 and 12 yearsMBS vs. medical/lifestyle therapyBetter glycemic control, more diabetes remission, less medication use; more anemia, fractures, and gastrointestinal adverse eventsShows durable efficacy with late trade-offsLABS [6]Multicenter longitudinal cohort; adults with obesity7 yearsRYGB vs. LAGBGreater long-term weight loss and better comorbidity improvement with RYGBDemonstrates procedure-specific durabilitySLEEVEPASS [7]Randomized clinical trial; adults with obesity10 yearsSG vs. RYGBBoth procedures remained effective; greater %EWL after RYGB; more reflux-related morbidity after SGHighlights SG vs. RYGB trade-offASGARD [8]Randomized clinical trial; adults with BMI 50–60 kg/m2 10 yearsDS vs. RYGBGreater BMI reduction after DS, but more adverse effects and nutritional burdenShows that higher potency may carry higher long-term costTeen-LABS adolescent longitudinal evidence [161720]Prospective multicenter cohort with long-term follow-up; adolescents with severe obesity3, 5, and 10 yearsMBS cohort; adolescent vs. adult gastric bypass comparison at 5 yearsSubstantial weight loss and metabolic remission; stronger T2DM/HTN remission than adults at 5 years, but more reoperation and low ferritin; durable benefit maintained at 10 yearsSupports adolescent durability while emphasizing lifelong surveillanceOseberg [21]Randomized clinical trial; adults with obesity and T2DM5 yearsSG vs. RYGBBetter diabetes remission, weight loss, and LDL reduction with RYGB; more reflux after SG; more hypoglycemia after RYGBRefines SG vs. RYGB in metabolic diseaseSwedish matched cohort in T2DM [22]Matched retrospective cohort; adults with obesity and T2DMLong-termRYGB vs. SGMore favorable long-term obesity-related outcomes with RYGB than SGProvides real-world metabolic comparator dataMBS vs. GLP-1 RAs [23]Observational cohort; adults with class II–III obesity2 yearsMBS vs. GLP-1 RasGreater weight loss and lower ongoing costs with surgeryPlaces MBS in the current incretin-era contextMBS = metabolic and bariatric surgery, RYGB = Roux-en-Y gastric bypass, T2DM = type 2 diabetes mellitus, LAGB = laparoscopic adjustable gastric banding, SG = sleeve gastrectomy, %EWL = percentage of excess weight loss, BMI = body mass index, DS = duodenal switch, HTN = hypertension, LDL = low-density lipoprotein, GLP-1 RA = glucagon-like peptide-1 receptor agonist. Landmark studies informing long-term outcomes after MBS MBS = metabolic and bariatric surgery, RYGB = Roux-en-Y gastric bypass, T2DM = type 2 diabetes mellitus, LAGB = laparoscopic adjustable gastric banding, SG = sleeve gastrectomy, %EWL = percentage of excess weight loss, BMI = body mass index, DS = duodenal switch, HTN = hypertension, LDL = low-density lipoprotein, GLP-1 RA = glucagon-like peptide-1 receptor agonist. LONG-TERM HARD OUTCOMES: SURVIVAL AND CARDIOVASCULAR BENEFITS Among the reported benefits of MBS, improved survival and cardiovascular outcomes may be the most clinically important. In the SOS study, patients who underwent surgery had significantly lower long-term mortality than those who received conventional obesity care, and the adjusted median life expectancy in the surgical group was 3.0 years longer [2]. Because of its long follow-up and near-complete ascertainment of mortality, this study remains one of the strongest demonstrations that MBS affects hard clinical outcomes rather than only intermediate metabolic markers. The survival signal is supported by cardiovascular data. Secondary analyses from the SOS cohort showed that MBS was associated with a lower risk of both fatal cardiovascular events and first-time total cardiovascular events [5]. Real-world evidence from the Veterans Affairs health system adds support from a large clinical population, showing lower long-term all-cause mortality in surgical patients than in matched non-surgical controls [24]. Summary-level evidence points in the same direction. A 2022 systematic review and meta-analysis found that MBS was associated with lower all-cause mortality and cardiovascular mortality, as well as lower incidence of several cardiovascular outcomes, including heart failure, myocardial infarction, and stroke, than non-surgical treatment [25]. Most long-term survival data still come from observational studies, but the consistency of these findings across cohorts and meta-analyses strongly suggests that the benefit of surgery extends well beyond the initial weight-loss period. DURABILITY OF WEIGHT LOSS AND METABOLIC BENEFITS The long-term clinical value of MBS is most evident in the sustained weight loss and metabolic improvements it offers. A 12-year prospective observational study by Adams et al. [3] demonstrated that RYGB resulted in lasting weight loss and significant remission or prevention of T2D, hypertension, and dyslipidemia. This study serves as one of the clearest examples of how surgery can provide enduring metabolic benefits rather than just temporary postoperative changes. Randomized evidence supports this conclusion. In the ARMMS-T2D collaborative analysis, MBS consistently outperformed medical and lifestyle interventions in terms of glycemic control, weight loss, and medication burden, with follow-up periods extending to 7 and even 12 years [4]. While T2D remission rates in the surgical group decreased from 18.2% at 7 years to 12.7% at 12 years, the medical/lifestyle group saw a drop from 6.2% to 0.0% by year 12 [4]. However, it is important to note that the surgical group also experienced higher rates of anemia, fractures, and gastrointestinal complications, highlighting the potential trade-offs associated with long-term durability [4]. This distinction is crucial. Long-term metabolic success should not be narrowly defined as permanent remission for every patient. The decline in remission rates observed in ARMMS-T2D is expected due to the progressive nature of T2D. Nevertheless, patients who underwent surgery maintained better glycemic control with reduced medication requirements. Thus, the long-term value of surgery lies not solely in achieving complete remission but also in alleviating disease burden and sustaining control over time [4]. Procedure-specific diabetes studies provide additional insights. The Oseberg trial indicated that RYGB was more effective than SG in achieving 5-year diabetes remission, weight loss, and reduction in low-density lipoprotein (LDL) cholesterol [21]. Conversely, pathological acid reflux was more prevalent following SG, while symptomatic postprandial hypoglycemia occurred more frequently after RYGB [21]. A matched Swedish cohort of T2D patients similarly reported more favorable long-term outcomes after RYGB compared to SG across various obesity-related metrics [22]. In summary, these findings suggest that long-term success after MBS is better characterized as sustained disease modification rather than a permanent cure. Meaningful long-term endpoints should encompass the prevention of new disease cases, a reduction in medication burden, and the maintenance of clinical control, even in instances of relapse [34]. PROCEDURE-SPECIFIC LONG-TERM OUTCOMES Long-term outcomes after MBS vary significantly by procedure, which is crucial for individualized decision-making. The LABS study found that RYGB resulted in significantly greater weight loss after 7 years compared to laparoscopic adjustable gastric banding and had more favorable long-term effects on T2D, dyslipidemia, and hypertension [6]. These results highlight the greater durability of RYGB compared to banding. The comparison between SG and RYGB is more complex. In the 10-year SLEEVEPASS trial, both procedures achieved sustained weight loss, but RYGB led to a higher percentage of EWL. However, reflux-related complications, including a higher prevalence of esophagitis, were more common after SG [7]. Recent randomized data from the Oseberg trial, involving patients with obesity and T2D, revealed a similar trade-off: RYGB offered better 5-year diabetes remission rates, greater weight loss, and lower LDL cholesterol, while pathological acid reflux was more frequent after SG, and symptomatic postprandial hypoglycemia occurred more often after RYGB [21]. In patients with a BMI of 50 to 60 kg/m2, the ASGARD trial demonstrated that DS achieved greater long-term reductions in weight and BMI compared to RYGB, but it also resulted in more adverse effects and nutritional complications [8]. The takeaway is clear: procedures with greater metabolic potency may provide better efficacy for severe obesity, but they often carry a higher physiological cost over time. Thus, the evidence specific to each procedure consistently emphasizes that long-term success depends not only on the surgical intervention itself but also on how well the long-term benefits and risks of a particular operation align with the patient’s metabolic profile and clinical priorities. ADOLESCENT MBS MBS in adolescents warrants distinct consideration because the balance of benefits and long-term burdens may differ from that observed in adults. In the Teen-LABS cohort, adolescents who underwent MBS achieved an average weight loss of 27% at three years, alongside significant improvements in T2D, hypertension, and dyslipidemia [16]. However, these benefits were accompanied by notable late complications, such as hypoferritinemia and the necessity for additional intra-abdominal procedures [16]. Comparative studies suggest that the main advantage of earlier surgery may lie in greater metabolic reversibility rather than in substantially greater weight loss itself. Five years after RYGB, adolescents and adults showed similar degrees of weight loss, yet adolescents had significantly higher remission rates of T2D and hypertension [17]. This pattern is clinically important. It suggests that intervention earlier in the course of severe obesity may capture a period in which obesity-related metabolic disease is still more reversible. That advantage, however, does not reduce the need for follow-up. Adolescents were more likely to undergo abdominal reoperations and to develop iron deficiency, underscoring that earlier surgery may improve long-term disease control while still demanding more vigilant nutritional and surgical surveillance [17]. Long-term data further support the durability of this effect. The 2024 Teen-LABS 10-year report revealed ongoing reductions in BMI and persistent remission of major obesity-related comorbidities during long-term follow-up [20]. LATE COMPLICATIONS AND THE PHYSIOLOGICAL COST OF DURABILITY Any discussion of the long-term value of MBS must consider the burden of late complications. In the ARMMS-T2D trial, MBS led to better long-term glycemic control and weight loss than medical/lifestyle therapy, but it was also associated with more late adverse events. Through 12 years, blood transfusion for anemia occurred in 12.0% after surgery vs. 3.1% with medical/lifestyle therapy, fractures in 13.3% vs. 5.2%, and gastric or anastomotic ulcer in 6.0% vs. 2.1%; gastrointestinal events such as abdominal pain, dumping syndrome, and nausea/vomiting were also more common after surgery [4]. This pattern underscores an important reality: the same intervention that offers durable metabolic benefits may also introduce a distinct long-term profile of adverse events. Procedure-specific studies further quantify these risks. In the 10-year SLEEVEPASS trial, esophagitis was more prevalent after SG than after RYGB (31% vs. 7%), although Barrett’s esophagus was observed in 4% of both groups and the overall reoperation rates were 15.7% and 18.5%, respectively [7]. Concerns about reflux after SG nevertheless extend beyond symptoms alone. A recent meta-analysis reported a pooled rate of 5.6% (95% confidence interval [CI], 3.5–8.8) for de novo Barrett’s esophagus after SG, together with increased risks of erosive esophagitis (risk ratio [RR], 3.37) and hiatal hernia (RR, 2.09) [26]. Furthermore, in a long-term follow-up study extending beyond 10 years after SG, de novo hiatal hernia was identified in 45% of evaluated non-converted patients and Barrett’s metaplasia in 15%, supporting continued concern regarding reflux-related sequelae after SG [27]. Bone health is another long-term concern that often receives insufficient attention. In the ARMMS-T2D trial, fractures occurred more frequently after MBS than after medical/lifestyle therapy (13.3% vs. 5.2%) [4]. This signal is supported by population-based data: in a Danish nationwide cohort, RYGB was associated with increased risk of any fracture (hazard ratio [HR], 1.56; 95% CI, 1.48–1.64) and major osteoporotic fracture (HR, 1.49; 95% CI, 1.35–1.64), whereas SG was also associated with increased risk of any fracture (HR, 1.38; 95% CI, 1.13–1.68), although the association with major osteoporotic fracture was less certain (HR, 1.43; 95% CI, 0.97–2.12) [28]. These findings highlight the importance of including skeletal health in routine long-term postoperative monitoring. The experience with DS further illustrates the issue of trade-offs. In the ASGARD trial, DS achieved greater long-term weight loss than RYGB, but this came at the cost of a distinctly higher nutritional burden: at 10 years, at least 1 vitamin deficiency was present in 84% after DS vs. 48% after RYGB, vitamin D deficiency in 19 vs. 9 patients, and severe protein-caloric malnutrition developed in 14% of DS patients, with 10% requiring revisional surgery [8]. Adolescent data suggest a similar pattern. In Teen-LABS, hypoferritinemia was present in 57% of patients and 13% underwent 1 or more additional intra-abdominal procedures at 3 years [16], while at 5 years adolescents undergoing gastric bypass had higher abdominal reoperation rates than adults and more frequent low ferritin levels (48% vs. 29%) [17]. These observations are consistent with current postoperative guidance. The ASMBS micronutrient guidelines emphasize regular biochemical surveillance and preventive supplementation [14], whereas multidisciplinary clinical practice guidelines recommend lifelong, structured follow-up within a chronic disease care model [15]. In the same vein, the recent IFSO position statement emphasizes that recurrent weight gain and relapse of obesity-related complications after MBS may warrant escalation of therapy, adjunctive pharmacotherapy, or revisional intervention, rather than a simplistic binary classification of success or failure [19]. MBS IN THE ERA OF INCRETIN-BASED PHARMACOTHERAPY The introduction of highly effective incretin-based pharmacotherapy has transformed the way we interpret the long-term outcomes of MBS. Trials of semaglutide and tirzepatide have demonstrated significant weight loss, with tirzepatide outperforming semaglutide in adults with obesity [910]. Three-year data for tirzepatide in adults with obesity and prediabetes indicate sustained weight loss and a reduced risk of progressing to T2D [11]. Consequently, the distinction between medical and surgical treatments has blurred, prompting new questions about the role of MBS in obesity care. Nonetheless, several key distinctions remain. First, the long-term effectiveness of pharmacotherapy appears to heavily depend on ongoing treatment. Maintenance studies of semaglutide and tirzepatide show that significant weight regain occurs after treatment is discontinued, whereas continued use helps maintain or enhance the initial benefits [1213]. Second, direct comparisons between MBS and incretin-based pharmacotherapy primarily rely on observational data rather than randomized trials. A 2025 cohort study found that MBS resulted in greater weight loss and lower ongoing healthcare costs compared to glucagon-like peptide-1 receptor agonists in patients with class II–III obesity [23]. Furthermore, surgery and pharmacotherapy should not be viewed merely as competing options. The GRAVITAS trial demonstrated that liraglutide improved glycemic control in patients with persistent or recurrent T2D following MBS, supporting the idea of using incretin-based pharmacotherapy as an adjunctive approach after MBS [29]. This perspective aligns with a broader understanding of obesity as a chronic disease, where weight regain or an incomplete metabolic response after MBS is addressed as part of ongoing care rather than seen as a binary failure [1819]. Whether incretin-based pharmacotherapy and MBS are best considered competing, sequential, or complementary strategies remains unclear. Until more direct comparative evidence is available, current findings suggest that MBS is the most established and durable treatment for severe obesity, while incretin-based pharmacotherapy is becoming an increasingly important option for comparison and adjunctive care. DISCUSSION Current long-term evidence indicates that MBS is the most effective treatment available for severe obesity and its associated metabolic complications. Research shows that the benefits of surgery extend beyond initial weight loss, leading to sustained metabolic improvements, reduced cardiovascular morbidity, and increased survival rates [23425]. Therefore, MBS should be viewed not merely as a weight-loss procedure, but as a treatment that modifies the disease of chronic obesity. Moreover, this data challenges an overly narrow definition of long-term success. While weight loss is an essential outcome, success should also encompass the remission or prevention of comorbidities, reduced reliance on medications, cardiovascular protection, and improvements in daily functioning and quality of life, all while considering potential late complications [342530]. This comprehensive perspective is crucial because complete remission rates may decline over time, even when clinical outcomes remain significantly better than those achieved through non-surgical means [4]. Additionally, fifteen-year follow-up data from the SOS cohort support the importance of patient-reported outcomes, revealing more favorable long-term quality-of-life trajectories following surgery compared to standard care [30]. Procedure choice remains a major theme in the long-term literature. RYGB has demonstrated greater durability compared to adjustable banding [6]. Both SG and RYGB are effective, but their long-term trade-offs differ, especially regarding reflux-related morbidity [72126]. DS offers superior efficacy for severe obesity but comes with higher physiological and nutritional costs [8]. Ultimately, the challenge lies not just in deciding whether to operate, but in selecting the procedure that best aligns with the patient's metabolic profile and clinical priorities. Additionally, the emergence of incretin-based pharmacotherapy has transformed the role of MBS in current practice. These medications can lead to significant weight loss, but their long-term effectiveness appears to be closely linked to ongoing treatment [910111213]. Current comparisons with MBS are primarily based on observational studies rather than randomized evidence [23]. Therefore, a realistic treatment model today emphasizes integration rather than replacement. Pharmacotherapy may postpone surgery, act as adjunctive treatment after relapse, or serve as an alternative for patients who are not ideal surgical candidates [1929]. Late complications, including nutritional, skeletal, and gastrointestinal issues, underscore that MBS is not a one-time solution. Structured lifelong multidisciplinary follow-up is essential for effective post-MBS care [1415]. Ultimately, long-term success hinges not only on the surgical procedure itself but also on the quality of the care that follows. CONCLUSION Long-term evidence indicates that MBS is one of the few interventions capable of achieving sustained disease modification in severe obesity. Its benefits include lasting weight loss, ongoing improvements in metabolic comorbidities, and increased survival rates with cardiovascular protection [23425]. These advantages vary by specific procedure and must be balanced against significant late complications and the necessity for lifelong multidisciplinary follow-up [41415]. Consequently, the long-term value of MBS should be assessed not only by weight loss but also by metabolic durability, procedure-specific trade-offs, and the quality of follow-up care. In current practice, MBS must also be considered in conjunction with the rapid advancement of incretin-based pharmacotherapy. While these agents have broadened non-surgical treatment options, their long-term benefits seem to rely on ongoing treatment [1213]. For the time being, MBS remains the most established and durable intervention for severe obesity. The future of obesity care will likely hinge on how surgical and pharmacological therapies are sequenced and combined to achieve optimal long-term outcomes for individual patients.